ASMB — Assembly Biosciences Inc
NASDAQ · Healthcare · Biotechnology
$35.61
+$0.43 (+1.22%)
Assembly Biosciences Inc (ASMB) is a biotechnology company listed on NASDAQ. It is led by Jason A. Okazaki J.D., based in Two Tower Place, South San Francisco, CA, United States, 94080, with about 73 employees. Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Net income was -$28.2M. ASMB currently screens at market cap $143.0M.
Use this ASMB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ASMB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ASMB SEC filings page. Lician reads the product cache first so this HTML stays unique to Assembly Biosciences Inc even when a live quote feed is slow.
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
ASMB Key Statistics
Market Cap
$142.97M
Volume
553,712
Previous Close
$35.28
Day Range
$35.19 – $37.00
EPS
-$6.69
Revenue
$0.00
Net Income
-$40.18M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
73
ASMB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$40.18M | -$61.23M | -$93.09M | -$129.85M |
| EPS (Diluted) | -$6.69 | -$13.38 | -$23.08 | -$3.00 |
Total Assets
$119.17M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$38.34M
Operating Cash Flow
-$51.12M
Free Cash Flow
$0.00
Assembly Biosciences Inc Company Information
- CEO, President & Director
- Jason A. Okazaki J.D.
- Headquarters
- Two Tower Place, South San Francisco, CA, United States, 94080
- Website
- www.assemblybio.com
- Phone
- 833 509 4583
- IPO / Founded
- 2010-12-17
- Sector
- Healthcare
- Industry
- Biotechnology